Efficacy and safety of hydrolyzed rice-protein formulas for the treatment of cow's milk protein allergy

Affiliation auteurs!!!! Error affiliation !!!!
TitreEfficacy and safety of hydrolyzed rice-protein formulas for the treatment of cow's milk protein allergy
Type de publicationJournal Article
Year of Publication2019
AuteursBocquet A., Dupont C., Chouraqui J.-P, Darmaun D., Feillet F., Frelut M.-L, Girardet J.-P, Hankard R., Lapillonne A., Roze J.-C, Simeoni U., Turck D., Briend A., CNSFP CNutr Frenc
JournalARCHIVES DE PEDIATRIE
Volume26
Pagination238-246
Date PublishedMAY
Type of ArticleReview
ISSN0929-693X
Mots-clésCow's milk allergy, Extensively hydrolyzed cow's milk protein formula, Growth, Hydrolyzed formulas, Hydrolyzed rice-protein formulas
Résumé

Foods for special medical purposes (FSMPs) with a protein fraction made of hydrolyzed rice protein (HRPs) have been on the market in Europe since the 2000s for the treatment of cow's milk protein allergy (CMPA). HRP formulas (HRPFs) are proposed as a plant-based alternative to cow's milk protein-based extensively hydrolyzed formulas (CMP-eHF) beside the soy protein formulas whose use in CMPA is controversial. HRPFs do not contain phytoestrogens and are derived from non-genetically modified rice. HRPFs are strictly plant-based apart from the addition of vitamin D-3 (cholecalciferol). As the amino acid content of rice proteins differs from that of human milk proteins, the protein quality of these formulas is improved by supplementation with free lysine, threonine, and tryptophan. The consumption of HRPFs has risen: for example, in France HRPFs account for 4.9% in volume of all formulas for children aged 0-3 years. Several studies have shown the adequacy of HRPFs in treating CMPA. They ensure satisfactory growth from the 1st weeks of life for infants and toddlers, both in healthy children and in those with CMPA. HRPFs can be used to treat children with CMPA either straightaway or in second intention in cases of poor tolerance to CMP-eHF for organoleptic reasons or for lack of efficacy. In France, the cost of HRPFs is close to that of regular infant or follow-on formulas. (C) 2019 Elsevier Masson SAS. All rights reserved.

DOI10.1016/j.arcped.2019.03.001